🚀 VC round data is live in beta, check it out!
Vistin Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Vistin Pharma and similar public comparables like Cassava Sciences, Adocia, Cognition Therapeutics, Zomedica and more.
Vistin Pharma Overview
About Vistin Pharma
Vistin Pharma ASA is a Norway based pharmaceutical company. It is principally engaged in the business activity of producing active pharmaceutical ingredients (APIs) and solid dosage forms for the pharmaceutical industry. The company has two business segments namely Pharmaceuticals and Energy Trading. The group has operations in Norway, Germany, Switzerland, Great Britain, Algeria and other countries.
Founded
2015
HQ
Employees
75
Website
Sectors
Financials (FY)
EV
$109M
Vistin Pharma Financials
Vistin Pharma reported last fiscal year revenue of $48M and EBITDA of $14M.
In the same fiscal year, Vistin Pharma generated $32M in gross profit, $14M in EBITDA, and $8M in net income.
Vistin Pharma P&L
In the most recent fiscal year, Vistin Pharma reported revenue of $48M and EBITDA of $14M.
Vistin Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $48M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $32M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 67% | XXX | XXX | XXX |
| EBITDA | — | XXX | $14M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 29% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 20% | XXX | XXX | XXX |
| Net Profit | — | XXX | $8M | XXX | XXX | XXX |
| Net Margin | — | XXX | 17% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Vistin Pharma Stock Performance
Vistin Pharma has current market cap of $107M, and enterprise value of $109M.
Market Cap Evolution
Vistin Pharma's stock price is $2.42.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $109M | $107M | -2.3% | XXX | XXX | XXX | $0.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVistin Pharma Valuation Multiples
Vistin Pharma trades at 2.3x EV/Revenue multiple, and 7.9x EV/EBITDA.
Vistin Pharma Financial Valuation Multiples
As of April 18, 2026, Vistin Pharma has market cap of $107M and EV of $109M.
Equity research analysts estimate Vistin Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vistin Pharma has a P/E ratio of 13.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $107M | XXX | $107M | XXX | XXX | XXX |
| EV (current) | $109M | XXX | $109M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 7.9x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 11.0x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.4x | XXX | XXX | XXX |
| P/E | — | XXX | 13.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 16.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Vistin Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Vistin Pharma Margins & Growth Rates
Vistin Pharma's revenue in the last fiscal year grew by 5%.
Vistin Pharma's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.3M for the same period.
Vistin Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 27% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Vistin Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Vistin Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Cassava Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Adocia | XXX | XXX | XXX | XXX | XXX | XXX |
| Cognition Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Zomedica | XXX | XXX | XXX | XXX | XXX | XXX |
| Sangamo Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vistin Pharma M&A Activity
Vistin Pharma acquired XXX companies to date.
Last acquisition by Vistin Pharma was on XXXXXXXX, XXXXX. Vistin Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Vistin Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVistin Pharma Investment Activity
Vistin Pharma invested in XXX companies to date.
Vistin Pharma made its latest investment on XXXXXXXX, XXXXX. Vistin Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Vistin Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Vistin Pharma
| When was Vistin Pharma founded? | Vistin Pharma was founded in 2015. |
| Where is Vistin Pharma headquartered? | Vistin Pharma is headquartered in Norway. |
| How many employees does Vistin Pharma have? | As of today, Vistin Pharma has over 75 employees. |
| Is Vistin Pharma publicly listed? | Yes, Vistin Pharma is a public company listed on Oslo Børs. |
| What is the stock symbol of Vistin Pharma? | Vistin Pharma trades under VISTN ticker. |
| When did Vistin Pharma go public? | Vistin Pharma went public in 2015. |
| Who are competitors of Vistin Pharma? | Vistin Pharma main competitors are Cassava Sciences, Adocia, Cognition Therapeutics, Zomedica. |
| What is the current market cap of Vistin Pharma? | Vistin Pharma's current market cap is $107M. |
| What is the current revenue of Vistin Pharma? | Vistin Pharma's last fiscal year revenue is $48M. |
| What is the current EV/Revenue multiple of Vistin Pharma? | Current revenue multiple of Vistin Pharma is 2.3x. |
| Is Vistin Pharma profitable? | No, Vistin Pharma is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.